# Fluorescence Cannot Replace Safety Checks in Gallbladder Surgery

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-fluorescence-cannot-replace-safety-2026-10-10/
> **Published:** 2026-10-10T22:50:18-04:00 | **Last Modified / Clinically Audited:** 2026-10-10T22:50:18-04:00
> **Clinical Summary:** medical cannabis research: Physician review of Does ICG-NIRF cholangiography replace the critical view of safety in laparoscopic cholecystectomy? A prospecti...

---

CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Does ICG-NIRF cholangiography replace the critical view of safety in laparoscopic cholecystectomy? A prospective evaluation on biliary visualization dynamics and the impact of inflammation..

Clinical Insight | CED Clinic
The practical concern is whether a visible fluorescent duct provides enough anatomical certainty to proceed safely. In this prospective cohort, simultaneous visualization of three major ducts increased from 16.7% at dissection onset to 46.9% before clipping, while the critical view of safety was achieved in 93.8% of cases. Acute cholecystitis independently predicted failure to visualize the common bile duct and common hepatic duct at the final assessment. These findings support continued reliance on standardized anatomical dissection. Fluorescence can assist orientation, but incomplete signals deserve particular caution in an inflamed operative field. The reported endpoints measure visualization and anatomical exposure, not a demonstrated reduction in bile duct injuries.

Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight

AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts.
Primary TopicClinical study review: Fluorescence Cannot Replace Safety Checks in Gallb.
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42844367/)

Table of Contents

- [Fluorescence Cannot Replace Safety Checks in Gallbladder Surgery](#Fluorescence_Cannot_Replace_Safety_Checks_in_Gallbladder_Surgery)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis)
- [Patient Communication](#Patient_Communication)
- [Dosing & Formulations](#Dosing_Formulations)
- [Safety & Side Effect Profile](#Safety_Side_Effect_Profile)
- [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics)
- [Mechanisms & Physiology](#Mechanisms_Physiology)
- [Research Limitations](#Research_Limitations)
- [Future Outlook](#Future_Outlook)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

# Fluorescence Cannot Replace Safety Checks in Gallbladder Surgery

In 96 patients undergoing laparoscopic gallbladder removal, fluorescent bile duct imaging improved as dissection progressed, but inflammation impaired visibility. The findings support fluorescence as an adjunct to the established critical view of safety.

What This Study Teaches Us
Among 96 patients, simultaneous three-duct fluorescence visualization increased from 16.7% at dissection onset to 46.9% before clipping, while critical view of safety achievement was 93.8%. Acute cholecystitis independently predicted final common bile duct and common hepatic duct non-visualization, with odds ratios of 4.48 and 3.80.

Why This Matters
Surgeons and patients should expect fluorescence reliability to vary during dissection and to decline with acute inflammation. These findings support retaining standardized anatomical verification and avoiding excessive confidence in an incomplete fluorescent image.

Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceSurgical endoscopyPublication Date2026Oct07Evidence LevelJournal ArticleFocus AreaFluorescence Cannot Replace Safety Checks in Gallbladder SurLead AuthorsKohei Mishima, Kazuya Hirukawa, Yuta Abe, Satoru MatsudaDOI10.1007/s00464-026-13438-5PMIDPMID: 42844367

Clinical Bottom Line
This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations.

Headline vs. Reality Truth Meter | Clinical Analysis

**Mainstream Media Claim:** Potential headline framing: Fluorescent imaging lets surgeons identify bile ducts and replace traditional gallbladder safety checks. No specific news article was supplied for comparison.

**Primary Journal Data:** The supplied PubMed abstract reports 96 patients, including 48 with acute cholecystitis. Simultaneous common bile duct, common hepatic duct, and cystic duct visualization rose from 16.7% at dissection onset to 46.9% before clipping. Critical view of safety achievement was 93.8%. Acute cholecystitis predicted final common bile duct and common hepatic duct non-visualization, with adjusted odds ratios of 4.48 and 3.80, respectively.

**Dr. Caplan’s Clinical Verdict:** Fluorescence offers supplementary anatomical information whose reliability changes with dissection and inflammation. This study supports preserving critical view of safety requirements and does not establish that fluorescence prevents injuries or can safely replace those requirements.

Primary Analysis | Does ICG-NIRF cholangiography replace th

**Study Overview:** While indocyanine green near-infrared fluorescence (ICG-NIRF) cholangiography is increasingly used to facilitate real-time biliary visualization, its ability to substitute for the Critical View of Safety (CVS) as a primary anatomical endpoint remains unclear. This study aimed to characterize the intraoperative dynamics of ICG-NIRF and evaluate the impact of acute cholecystitis (AC) on its reliability. In this prospective study of 96 consecutive patients (48 AC; 48 non-AC), biliary visualization was assessed at three milestones: T1 (dissection onset), T2 (CVS declaration), and T3 (pre-clipping). Patients received ICG (1.25 mg) at induction. Dissection followed the Tokyo Guidelines 2018 (TG18) framework using standardized subserosal-inner layer technique to achieve the CVS. The primary endpoint was the simultaneous visualization of the common bile duct (CBD), common hepatic duct (CHD), and cystic duct (CyD). Factors affecting visualization were analyzed using generalized estimating equations and multivariable regression. CVS was achieved in 93.8% of cases, whereas simultaneous three-duct NIRF visualization was achieved in only 16.7% at T1, showing significant temporal improvement by T3 (46.9%; OR 4.61, p < 0.001). Multivariable analysis identified AC as the sole independent predictor of both CBD (OR 4.48, p = 0.016) and CHD (OR 3.80, p = 0.003) non-visualization at T3, with identification failure rates increasing stepwise with TG18 severity (p = 0.001). ICG-NIRF signals follow a dissection-dependent trajectory that is consistently attenuated by inflammation. Because the CVS provides anatomical certainty far beyond that of fluorescence alone, ICG-NIRF complements but does not replace the standardized dissection framework. In cases of severe AC, surgeons must prioritize meticulous surgical maneuvers over potentially unreliable fluorescence signals.

**Primary Source & Scope:** Published in *Surgical endoscopy* (2026Oct07) conducted by Kohei Mishima, Kazuya Hirukawa, Yuta Abe, Satoru Matsuda. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42844367/) | **Primary Record:** DOI: 10.1007/s00464-026-13438-5 | PMID: 42844367

How Strong Is This Evidence?
This prospective study assessed 96 consecutive patients at three predefined operative milestones, with equal numbers of acute and non-acute cases. Generalized estimating equations addressed repeated observations, and multivariable regression identified inflammation-related associations; reported p values supported temporal improvement and selected non-visualization predictors. Confidence intervals and full model specifications are absent from the supplied abstract, which limits assessment of precision and model stability.

Where This Paper Deserves Skepticism
The observational design leaves potential confounding by case complexity, surgeon assessment, elapsed time after injection, and other incompletely described variables. The abstract does not specify independent verification of critical view of safety declarations or image interpretation, and small severity subgroups could produce uncertain estimates. Simultaneous three-duct visibility and critical view of safety achievement are different endpoints, so their percentages do not measure equivalent anatomical performance.

What This Paper Does Not Show
This study does not prove that ICG-NIRF reduces bile duct injuries or that any fluorescence-based replacement strategy is safe. It does not establish an optimal dye regimen, validate a regulatory change, or show that failure to visualize a duct predicts an individual patient’s postoperative outcome.

How This Fits With the Broader Clinical Conversation

Fluorescence-guided surgery reflects a wider effort to provide surgeons with real-time anatomical information. Its clinical value depends on the decision it supports, the reliability of the signal, and the established safety checks surrounding its use. Better visibility is a useful process measure, while prevention of injury requires patient-outcome evidence.

The critical view of safety assesses defined relationships at the gallbladder. Fluorescent cholangiography depicts bile-containing structures within the limits of signal detection. These approaches answer related anatomical questions, and a successful fluorescent image does not automatically satisfy every critical view criterion.

Inflammation is a recurring challenge in gallbladder surgery because it changes tissue planes and complicates exposure. This cohort adds a quantified association between acute cholecystitis and failure to visualize major ducts. Larger comparative studies would be needed to determine how that association should influence specific operative strategies.

Editorial Commentary

*The clinically meaningful result is the gap between frequent achievement of the critical view of safety and incomplete simultaneous fluorescence visualization. Even at the final milestone, all three target ducts were visible in fewer than half of cases. A supplementary image cannot be assumed to provide the anatomical verification required before clipping.*

*Acute cholecystitis deserves specific attention because it independently predicted non-visualization of both major ducts assessed at the final milestone. The severity association makes this especially relevant to difficult operations. The appropriate response is disciplined anatomical assessment and a defined plan for inadequate exposure; the study provides no evidence that a higher dye dose solves the problem.*

*The reported improvement over time is useful, but its interpretation requires restraint. Dissection progressed while time after injection also increased. The data support a changing intraoperative signal, without establishing the separate contribution of each factor or demonstrating fewer injuries.*

What a Careful Reader Should Take Away
Treat ICG-NIRF as an adjunct to anatomical verification, with particular caution during acute cholecystitis. Patients can ask how their surgeon handles incomplete imaging and inability to achieve safe exposure.

[https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Safety](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[💊Drug Interactions](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask)

Evidence Interpretation Guide

## How to Interpret This Clinical Study

Navigating biomedical publications regarding Does ICG-NIRF cholangiography replace the cri requires reviewing study methodology and patient eligibility.

### Three Rules for Critical Reading

**Keep the endpoints separate**simultaneous visualization of three ducts and achievement of the critical view of safety assess different anatomical requirements.

**Critical Rule**Read the reported 4.48 and 3.80 estimates as adjusted odds ratios for non-visualization, and look for confidence intervals and absolute event rates before translating them into risk.

**Critical Rule**Recognize that later imaging followed both further dissection and more time after injection; the supplied results do not isolate those effects or establish injury reduction.

Key Evaluation Question
Does fluorescence provide enough independently verified anatomical information to change surgical decisions safely, especially when acute inflammation obscures the ducts?

The Patient Question
How will you confirm the anatomy and adjust the surgical plan if inflammation prevents a clear fluorescent image or a critical view of safety?

The Bottom Line
Fluorescence visibility improved during surgery but remained incomplete and inflammation-sensitive. The evidence supports supplementary use alongside established anatomical safety checks.

CED Perspective Lens

## CED Perspective Lens: Eight Clinical Viewpoints

Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives

Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care.

#### Clinical Evidence Synthesis

The prospective cohort included 96 consecutive patients, evenly divided between acute cholecystitis and non-acute cases. Investigators assessed fluorescent anatomy at dissection onset, critical view of safety declaration, and immediately before clipping. This repeated-assessment design documents how visibility changes during an operation, an important distinction from studies that report a single final image.

Simultaneous visualization of all three specified ducts increased from 16.7% initially to 46.9% before clipping, with a reported odds ratio of 4.61 and p < 0.001. Critical view of safety achievement reached 93.8%. These endpoints describe different anatomical assessments, so their percentages cannot be treated as a direct comparison of injury prevention.

Lens takeawayThe study supports fluorescence as supplementary anatomical information, while its measured endpoints do not establish comparative protection against surgical injury.

#### Patient Communication

Patients may reasonably assume that an illuminated bile duct makes gallbladder surgery straightforward. A more accurate explanation is that fluorescence adds a visual cue, while the surgeon still needs to establish anatomical relationships through careful exposure. In this cohort, all three target ducts were visible together in fewer than half of cases before clipping.

For patients with acute cholecystitis, the discussion should acknowledge that inflammation can make the image less dependable. The reported association concerns duct visibility, not an individualized prediction of injury. Patients can ask how the surgical team confirms anatomy when fluorescence is incomplete and what alternative operative plan is available if safe exposure cannot be achieved.

Lens takeawayPatients should understand fluorescence as an additional surgical aid and ask how uncertain anatomy will be handled during their operation.

#### Dosing & Formulations

Every participant received 1.25 mg of indocyanine green at anesthesia induction. That fixed protocol provides a useful reference for the reported visualization results. The study did not compare different doses, weight-adjusted regimens, injection intervals, or formulations, so its findings cannot establish which administration strategy produces the best images.

Timing also complicates interpretation. Later observations occurred after both additional dissection and additional time following injection. The reported abstract does not separate those contributions. A clinician should therefore avoid concluding that poor visibility calls for a larger dose or that this particular induction-time regimen is optimal for severe inflammation.

Lens takeawayThe 1.25 mg induction-time protocol describes the study conditions; it does not establish an optimal dose or justify automatic dose escalation.

#### Safety & Side Effect Profile

The central safety concern is anatomical misinterpretation. A fluorescent signal can assist recognition of a duct, but it does not establish every relationship required for safe clipping and division. The critical view of safety requires clearance of the hepatocystic triangle, separation of the lower gallbladder from the liver bed, and confirmation that only two structures enter the gallbladder.

Acute cholecystitis independently predicted failure to visualize the common bile duct and common hepatic duct at the final milestone. That finding warrants caution when the field is inflamed. The supplied abstract does not report dye-related adverse events or comparative bile duct injury outcomes; those risks cannot be quantified from these results.

Lens takeawayIncomplete fluorescence should prompt continued anatomical caution, particularly during acute inflammation, and should never be interpreted as permission to clip uncertain structures.

#### Regulatory & Policy Dynamics

Fluorescence-guided surgery requires access to a compatible near-infrared imaging system, an indocyanine green administration protocol, and staff familiar with image interpretation. Availability may differ between surgical facilities. The study’s results describe performance under its own protocol and do not establish reimbursement rules, device requirements, or jurisdiction-specific authorization.

For hospital governance, the relevant finding is that fluorescent visibility remained incomplete despite substantial improvement during surgery. A local safety protocol should preserve established anatomical verification and define escalation options when exposure is inadequate. Purchasing imaging equipment does not by itself validate a replacement pathway for the critical view of safety.

Lens takeawayInstitutions should pair fluorescence access with training and explicit anatomical safety standards, without treating equipment availability as evidence of surgical equivalence.

#### Mechanisms & Physiology

Indocyanine green is taken up by the liver and excreted into bile, where near-infrared imaging can detect its fluorescence. The camera must detect that signal through the operative tissues. Tissue thickness, background fluorescence, and exposure can affect how clearly a duct appears; these factors provide a physiological explanation for changing intraoperative visibility.

The cohort showed stronger visualization at later surgical milestones and poorer final visualization in acute cholecystitis. Inflammatory edema and altered tissue planes are plausible contributors, but the reported analysis does not isolate their individual effects.

The measured association supports caution about signal reliability in inflammation. It does not identify a single biological cause for every missing duct image.

Lens takeawayFluorescent visibility depends on both biliary signal and tissue exposure, so an absent image does not establish an absent anatomical structure.

#### Research Limitations

A 96-patient prospective cohort can describe visualization patterns, but it cannot reliably establish differences in uncommon events such as major bile duct injury. There was no reported randomized comparison between fluorescence-guided surgery and a replacement strategy. The three-duct fluorescence endpoint also differs from the anatomical criteria used to declare the critical view of safety.

Repeated-measures analysis is appropriate for observations collected within the same patient, and multivariable regression addresses measured covariates. However, the supplied abstract does not provide confidence intervals, full adjustment variables, independent image adjudication, or severity subgroup sizes. Surgeon judgment, case complexity, and elapsed time after injection may influence the observed associations.

Lens takeawayThese results characterize image reliability under one protocol; they cannot establish injury prevention, universal performance, or the safety of replacing anatomical verification.

#### Future Outlook

Future studies should compare clearly specified dosing and injection-timing protocols across acute cholecystitis severity groups. Independent assessment of recorded images and critical view of safety achievement would help distinguish technical image quality from surgeon interpretation. Reporting confidence intervals and severity-specific denominators would make estimates more useful for clinical planning.

Larger multicenter studies are needed to examine patient outcomes, including bile duct injuries, operative complications, and use of alternative surgical strategies. Those outcomes should be evaluated separately from duct visibility.

The immediate research priority is to determine when fluorescence changes a surgical decision safely and when inflammation makes its information insufficient for that decision.

Lens takeawayFuture research should connect fluorescence performance to verified surgical decisions and patient outcomes before any replacement claim enters routine clinical practice.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](http://CEDclinic.com/book)
 [Cannabis Care](http://CEDclinic.com/book)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Fluorescence+Cannot+Replace+Safety+Checks+in+Gallbladder+Surgery&url=https%3A%2F%2Fcedclinic.com%2Fced-fluorescence-cannot-replace-safety-2026-10-10%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-fluorescence-cannot-replace-safety-2026-10-10%2F)
[BlueSky](https://bsky.app/intent/compose?text=Fluorescence+Cannot+Replace+Safety+Checks+in+Gallbladder+Surgery%20https%3A%2F%2Fcedclinic.com%2Fced-fluorescence-cannot-replace-safety-2026-10-10%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Source: Does ICG-NIRF cholangiography replace the critical view of safety in laparoscopic cholecystectomy? A prospective evaluation on biliary visualization dynamics and the impact of inflammation.](https://pubmed.ncbi.nlm.nih.gov/42844367/)

Related Reading at CED ClinicContinue exploring the evidence[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)

More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications.

[More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)

More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia.

[More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility.

[More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

## Frequently Asked Questions

Can fluorescent imaging replace the critical view of safety?

These findings support keeping the critical view of safety as the anatomical standard. Fluorescence provided incomplete three-duct visualization even before clipping and was less dependable in acute cholecystitis.

What is the critical view of safety?

It is an anatomical verification method used before dividing structures during gallbladder removal. It requires clearing the hepatocystic triangle, separating the lower gallbladder from the liver bed, and confirming that only two structures enter the gallbladder.

How many patients were studied?

The prospective study included 96 consecutive patients: 48 with acute cholecystitis and 48 without acute cholecystitis.

How often were all three ducts visible with fluorescence?

The common bile duct, common hepatic duct, and cystic duct were simultaneously visible in 16.7% of cases at dissection onset and 46.9% before clipping.

How did acute inflammation affect the images?

Acute cholecystitis predicted final non-visualization of the common bile duct and common hepatic duct. The adjusted odds ratios were 4.48 and 3.80, respectively. Identification failures also increased with Tokyo Guidelines 2018 severity.

Do those odds ratios mean the risk was four times higher?

They describe adjusted odds of non-visualization, not risk ratios. Converting them into an absolute risk difference requires the underlying event rates and model details.

What dose of indocyanine green was used?

Patients received 1.25 mg at anesthesia induction. The study did not compare dosing strategies, so it does not establish an optimal dose or injection time.

Did the study prove that fluorescence prevents bile duct injuries?

The supplied abstract reports visualization and critical view of safety endpoints. It does not provide comparative injury data sufficient to establish a reduction in bile duct injuries.

What does a missing fluorescent duct signal mean?

It means that the imaging system did not adequately show that duct at that moment. Tissue coverage, inflammation, timing, and imaging conditions can affect visibility. The surgeon must resolve anatomy through appropriate surgical assessment.

What should a patient ask before gallbladder surgery?

Ask how the surgeon confirms anatomy before clipping, whether fluorescence is available, and what approach is planned if inflammation prevents safe exposure. The response should describe an anatomical safety strategy and options for an uncertain operative field.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).